Cite
HARVARD Citation
Hayashi, H. et al. (2022). Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L). Lung cancer. pp. 38-45. [Online].